Click here to read the original notifications for:-

Amoxicillin Capsules, Buprenorphine with naloxone, compound electrolytes, Fluoxetine Capsules & Dispersible Tablets, Clindamycin Capsules 150 mg, Levomepromazine Inj,  Moxifloxacin Inj (HML ONLY), Ondansetron Tablets and Paraffin White Soft.

In all cases we also suggest you review the analysis available for many product  enabling you to improve your profitability by not changing immediately.

Most of these products will have DUAL listings in the Pharmaceutical Schedule & where applicable HML from 1 November 2019 until 31 March 2020.

We ask that you continue to order the incumbent brand(s) to ensure supplies move through the supply chain with no risk to either supplier, wholesaler or pharmacy.

ProPharma /PWR will implement automatic replacement where applicable.

As of the date of this notification ProPharma / PWR cannot accept any of the products listed to be delisted for credit under any circumstances.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 April 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesale and pharmacy, do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author